Tag: David Holtzman

$4.5 million supports pathbreaking neuroimmunology research

Washington University School of Medicine in St. Louis has received a three-year $4.5 million grant from the Carol and Gene Ludwig Family Foundation, aimed at advancing research on neuroimmunology and neurodegeneration with the ultimate goal of developing new treatments for Alzheimer’s disease. Administered by WashU Medicine’s Brain Immunology & Glia (BIG) Center, the Carol and Gene […]

Immunotherapy for Alzheimer’s disease shows promise in mouse study

Alzheimer’s disease starts with a sticky protein called amyloid beta that builds up into plaques in the brain, setting off a chain of events that results in brain atrophy and cognitive decline. The new generation of Alzheimer’s drugs — the first proven to change the course of the disease — work by tagging amyloid for […]

Tau-based biomarker tracks Alzheimer’s progression

Two pathologies drive the progression of Alzheimer’s disease. Early on, amyloid beta plaques lead the way, but around the time cognitive symptoms arise, tau tangles take over as the driving force and cognition steadily declines. Tracking the course of the disease in individual patients has been challenging because there’s been no easy way to measure […]